949 completed, 312 unknown, 241 recruiting, 205 terminated. 1109 Phase 2, 543 Phase 3, 400 Phase 1, 66 Not applicable, 44 Phase 4.
Follow Fluorouracil: new trials by email Literature Review of Fluorouracil trials Research Report on Fluorouracil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 820 | 2027-06-30 | 2026-09-29 |
| Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 34 | 2027-04-01 | 2026-11-04 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2027-01-04 | 2026-11-05 |
| Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer Tovecimig, Irinotecan, Leucovorin - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 25 | 2026-12-31 | 2026-11-05 |
| Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma Biospecimen Collection, Echocardiography Test, Fluorouracil - Childhood Posterior Fossa Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 70 | 2026-12-11 | 2026-09-30 |
| Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer Biospecimen Collection, Computed Tomography, Fluorouracil - Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 30 | 2026-12-01 | 2026-09-02 |
| Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab - Colo-rectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | CytomX Therapeutics | 368 | 2026-12-01 | 2026-10-28 |
| QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients Intervention 1 - Drug QL1706 (Iparomlimab and Tuvonralimab) Intervention 2 - Drug Lenvatinib Intervention 3 - Drug FOLFOX Chemotherapy (Oxaliplatin, Fluorouracil, and Levoleucovorin Calcium) - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 33 | 2026-12-01 | 2026-11-12 |
| A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 4 | Not yet recruiting | Astellas Pharma Global Development, Inc. | 50 | 2026-11-30 | 2026-09-21 |
| Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer Oxaliplatin, 5-Fluorouracil, Capecitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 3 | Not yet recruiting | Zhai Wenlong | 90 | 2026-11-30 | 2026-11-04 |
| A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer Irinotecan, Oxaliplatin, GFH276 - CRC | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 150 | 2026-11-15 | 2026-11-06 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin] - Pancreatic Cancer, Borderline Resectable Pancreatic Cancer | Not applicable | Recruiting | IMGT Co., Ltd. | 366 | 2026-11-04 | 2026-11-09 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 229 | 2026-11-01 | 2026-10-16 |
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2026-10-26 | 2026-10-29 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 400 | 2026-10-23 | 2026-11-16 |
| Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Esophageal Adenocarcinoma | Phase 2 | Recruiting | Duke University | 60 | 2026-10-21 | 2026-11-04 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-21 | 2026-11-16 |
| TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread TQB2922 injection (subcutaneous administration), Oxaliplatin, Calcium folinate (leucovorin calcium) - Colorectal Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 64 | 2026-10-20 | 2026-09-28 |
Showing 20 of 1990. Sign in to see all of them.
Colorectal Neoplasms (503) · Rectal Neoplasms (268) · Colonic Neoplasms (220) · Pancreatic Neoplasms (191) · Stomach Neoplasms (190) · Esophageal Neoplasms (135) · Breast Neoplasms (120) · Neoplasm Metastasis (118) · Squamous Cell Carcinoma of Head and Neck (97) · Neoplasms (94) · Head and Neck Neoplasms (92) · Adenocarcinoma Of Esophagus (73) · Esophageal Squamous Cell Carcinoma (65) · Carcinoma, Hepatocellular (57) · Adenocarcinoma (43)
National Cancer Institute (NCI) (82) · Sun Yat-sen University (61) · M.D. Anderson Cancer Center (39) · Fudan University (35) · Alliance for Clinical Trials in Oncology (32) · European Organisation for Research and Treatment of Cancer - EORTC (31) · Memorial Sloan Kettering Cancer Center (31) · UNICANCER (31) · Hoffmann-La Roche (30) · Merck Sharp & Dohme LLC (29) · Sanofi (29) · AstraZeneca (22) · GERCOR - Multidisciplinary Oncology Cooperative Group (22) · ImmunityBio, Inc. (21) · Eli Lilly and Company (19)
United States (895) · China (392) · France (243) · Germany (199) · Italy (189) · Spain (175) · United Kingdom (165) · Canada (159) · Japan (134) · South Korea (134) · Belgium (118) · Taiwan (110) · Australia (109) · Poland (81) · Brazil (71)
Norman Wolmark, MD (9) · David J. Adelstein, MD (6) · Al B. Benson, MD, FACP (5) · Alfredo Falcone, MD (5) · Howard S. Hochster, MD (5)
PMID 36306483, PMID 31268130, PMID 32816630, PMID 40341124, PMID 21997132, PMID 33356421, PMID 40207789, PMID 33439695, PMID 34037241, PMID 35623069, PMID 37139963, PMID 41252656, PMID 12049862, PMID 12540794, PMID 17960012, PMID 20797891, PMID 21561347, PMID 23265711, PMID 23493136, PMID 24982463, PMID 26187751, PMID 26861604, PMID 27275632, PMID 27722750, PMID 27986363, PMID 28006055, PMID 28237539, PMID 28797458, PMID 29471013, PMID 30293873, PMID 30679026, PMID 31070690, PMID 31378656, PMID 31811950, PMID 32085892, PMID 32418078, PMID 32939319, PMID 33538338, PMID 33684371, PMID 33792646, PMID 34795131, PMID 34905388, PMID 35594613, PMID 36525610, PMID 36572280, PMID 36940261, PMID 37037952, PMID 37699333, PMID 37957132, PMID 38315963
2023 (22), 2017 (19), U10CA032102 (18), 2016 (17), 2018 (15), 2014 (14), 2015 (13), 2025 (13), U10CA031946 (13), U10CA180820 (13), 2019 (10), U10CA021115 (10), P30CA033572 (9), U10CA180868 (9), 2008 (8)